NULISA™ CNS Disease Panels
Ultra-sensitive, multiplexed quantification of neuro-specific and inflammatory proteins.
Detect and track key biomarkers of amyloid and tau pathologies, synaptic function, neurodegeneration, and inflammation.
Biomarkers of disease progression and therapeutic response are transforming the field of neurology, enabling earlier diagnosis, improved patient stratification, and more precise evaluation of treatment efficacy.
The NULISA CNS Disease Panels enable robust profiling of the most important biomarkers of neurodegenerative disease progression and therapeutic response at the lowest limit of detection, in both plasma and CSF.
NULISAseq™ Neuro 220 Panel
NULISAseq™ CNS Disease Panel 120
Providing best-in-class sensitivity and robust, multiplexed analysis of 120+ neuro-specific and inflammatory proteins associated with neurodegenerative disorders.
READ THE PUBLICATION
NULISA: a proteomic liquid biopsy platform with attomolar sensitivity
This Nature Communications paper demonstrates the exceptional performance of the NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) in detecting biologically important low-abundance biomarkers.
Why choose Sapient as your NULISA CNS Disease Panel provider?
- Robust measures of the most relevant cytokines, chemokines, and inflammatory mediators
- Complementary omics approaches to orthogonally validate NULISA data or integrate additional molecular data layers
- Integrative statistical and ML analysis of NULISA data with additional phenotypic and/or omics data
- Biological contextualization of identified markers using our DynamiQ™ Insights Engine
Request a NULISA™ CNS Disease Panel
"*" indicates required fields